BridgeBio Pharma (BBIO) Free Cash Flow Growth (1y) (2019 - 2026)
BridgeBio Pharma (BBIO) Free Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 137.65% |
| 10 | BridgeBio Pharma | 16.45 Bn | 15.51 Bn | 184.58 Mn | 0.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.95% |
| Dec 31, 2025 | 70.56% |
| Sep 30, 2025 | 39.38% |
| Jun 30, 2025 | -207.11% |
| Mar 31, 2025 | 9.53% |
| Dec 31, 2024 | -56.61% |
| Sep 30, 2024 | -24.69% |
| Jun 30, 2024 | 166.20% |
| Mar 31, 2024 | -52.58% |
| Dec 31, 2023 | -27.27% |
| Sep 30, 2023 | -9.86% |
| Jun 30, 2023 | -245.17% |
| Mar 31, 2023 | 10.57% |
| Dec 31, 2022 | 32.27% |
| Sep 30, 2022 | -10.19% |
| Jun 30, 2022 | 65.00% |
| Mar 31, 2022 | -5.79% |
| Dec 31, 2021 | -59.20% |
| Sep 30, 2021 | 9.43% |
| Jun 30, 2021 | -6.78% |